Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Pipeline Review, H2 2017

Published: Oct, 2017 | Pages: 58 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Pipeline Review, H2 2017

Summary

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Glycogen synthase kinase 3 beta also known as GSK3B is an enzyme encoded by the GSK3B. It constitutively activate protein kinase that acts as a negative regulator in the hormonal control of glucose homeostasis, Wnt signaling and regulation of transcription factors and microtubules. It mediates the development of insulin resistance by regulating activation of transcription factors. It regulates protein synthesis by controlling the activity of initiation factor 2B (EIF2BE/EIF2B5) in the same manner as glycogen synthase. It plays an important role in ERBB2-dependent stabilization of microtubules at the cell cortex. It phosphorylates MACF1, inhibiting its binding to microtubules which is critical for its role in bulge stem cell migration and skin wound repair. It regulates the circadian clock via phosphorylation of the major clock components including ARNTL/BMAL1, CLOCK and PER2. 

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) pipeline Target constitutes close to 20 molecules. Out of which approximately 13 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 9 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 5 molecules, respectively. Report covers products from therapy areas Central Nervous System, Oncology, Metabolic Disorders, Cardiovascular, Genetic Disorders, Musculoskeletal Disorders and Ophthalmology which include indications Alzheimer's Disease, Pancreatic Cancer, Amyotrophic Lateral Sclerosis, Lung Cancer, Type 2 Diabetes, Breast Cancer, Cognitive Impairment, Dyskinesia, Glioblastoma Multiforme (GBM), Hypertension, Kidney Cancer (Renal Cell Cancer), Liver Cancer, Menkes Disease (Kinky Hair Disease), Multiple Sclerosis, Myotonic Dystrophy, Neuroblastoma, Neurodegenerative Diseases, Ovarian Cancer, Retinitis Pigmentosa (Retinitis) and Tauopathies. 

The latest report Glycogen Synthase Kinase 3 Beta - Pipeline Review, H2 2017, outlays comprehensive information on the Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1)
- The report reviews Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Overview 7
Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Therapeutics Development 8
Products under Development by Stage of Development 8
Products under Development by Therapy Area 9
Products under Development by Indication 10
Products under Development by Companies 12
Products under Development by Universities/Institutes 15
Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Therapeutics Assessment 17
Assessment by Mechanism of Action 17
Assessment by Route of Administration 18
Assessment by Molecule Type 19
Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Companies Involved in Therapeutics Development 21
Actuate Therapeutics Inc 21
AMO Pharma Ltd 21
Angelini Group 21
DiaMedica Therapeutics Inc 22
Jeil Pharmaceutical Co Ltd 22
Mitsubishi Tanabe Pharma Corp 23
Neurim Pharmaceuticals Ltd 23
Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Drug Profiles 24
9-ING41 - Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
AP-001 - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
AP-1 - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
DM-204 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
Drug to Inhibit GSK3-Beta for Alzheimer's Disease - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
IB-AD - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
JGK-263 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
manzamine A - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
Neu-120 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
Small Molecule to Inhibit GSK-3 Beta for Menkes Disease and Tauopathies - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
Small Molecule to Inhibit GSK3B for Ovarian Cancer - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
Small Molecule to Inhibit GSK3b for Type 2 Diabetes - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
Small Molecules to Inhibit BACE-1 and GSK-3 Beta for Alzheimer's Disease - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
Small Molecules to Inhibit CDK1, CDK5 and GSK3b for Alzheimer's Disease - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
Small Molecules to Inhibit GSK-3 Beta for Alzheimer's Disease - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
Small Molecules to Inhibit GSK-3 Beta for CNS Disorders - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
Small Molecules to Inhibit GSK3B and Activate Nrf2 for Alzheimer's Disease - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
Small Molecules to Inhibit GSK3B for Amyotropic Lateral Sclerosis - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
Synthetic Peptides to Inhibit GSK3B for Cardiovascular, Central Nervous System and Metabolic Disorders - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
tideglusib - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Dormant Products 48
Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Discontinued Products 50
Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Product Development Milestones 51
Featured News & Press Releases 51
Sep 25, 2017: AMO Pharma Reports Update on Positive Interim Analysis for the First Cohort of Phase IIa Congenital Myotonic Dystrophy Study 51
Jul 27, 2017: AMO Pharma Receives FDA Orphan Drug Designation for AMO-02 for Treatment of Congenital Myotonic Dystrophy 51
May 30, 2017: AMO Pharma Announces FDA Fast Track Designation For AMO-02 For Treatment Of Congenital Myotonic Dystrophy 52
Apr 03, 2017: Actuate Therapeutics' Programs Highlighted in Clinical Cancer Research 52
Aug 10, 2016: AMO Pharma Initiates Phase 2 Clinical Trial in UK for AMO-02 for Treatment of Congenital and Juvenile Onset Myotonic Dystrophy 53
Mar 29, 2016: FDA grants 9-ING-41 an Orphan Drug Designation for treatment of glioblastoma 53
Dec 18, 2015: Actuate Therapeutics Provides Update On 9-ING4 54
Nov 19, 2015: Actuate Therapeutics Presents Data On 9-ING41 at the Society of Neuro Oncology meeting 54
Apr 20, 2015: Actuate Therapeutics Provides Update On GSK-3B at the AACR Meeting 54
Dec 03, 2012: Alzheimer's researcher reveals a protein's dual destructiveness - and therapeutic potential 54
Sep 27, 2012: DiaMedica's DM-204 Selected For Poster Presentation At 2012 American Heart Association's Scientific Conference 54
Jul 20, 2012: Noscira Presents Phase II Results Of tideglusib At Alzheimer's Association International Conference 2012 55
Jun 14, 2012: DiaMedica Announces Summary Of DM-204 Program At 72nd Annual American Diabetes Association Conference 55
Jun 01, 2012: DiaMedica's DM-204 Program Selected For Presentation At American Diabetes Association's 72nd Scientific Conference 56
Mar 22, 2012: DiaMedica Provides Update On DM-204 56
Appendix 57
Methodology 57
Coverage 57
Secondary Research 57
Primary Research 57
Expert Panel Validation 57
Contact Us 57
Disclaimer 58

List of Tables

Number of Products under Development by Stage of Development, H2 2017 8
Number of Products under Development by Therapy Areas, H2 2017 9
Number of Products under Development by Indication, H2 2017 10
Number of Products under Development by Companies, H2 2017 12
Products under Development by Companies, H2 2017 13
Products under Development by Companies, H2 2017 (Contd..1), H2 2017 14
Number of Products under Investigation by Universities/Institutes, H2 2017 15
Products under Investigation by Universities/Institutes, H2 2017 16
Number of Products by Stage and Mechanism of Actions, H2 2017 17
Number of Products by Stage and Route of Administration, H2 2017 18
Number of Products by Stage and Molecule Type, H2 2017 20
Pipeline by Actuate Therapeutics Inc, H2 2017 21
Pipeline by AMO Pharma Ltd, H2 2017 21
Pipeline by Angelini Group, H2 2017 22
Pipeline by DiaMedica Therapeutics Inc, H2 2017 22
Pipeline by Jeil Pharmaceutical Co Ltd, H2 2017 23
Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2017 23
Pipeline by Neurim Pharmaceuticals Ltd, H2 2017 23
Dormant Products, H2 2017 48
Dormant Products, H2 2017 (Contd..1), H2 2017 49
Discontinued Products, H2 2017 50